Traumatic brain injury Injury, Occupational Diseases, Poisoning
Conditions
Interventions
Current interventions as of 03/06/2026:
Beta-Blockers Domain:
Domain-Specific Exclusion Criteria: Contraindications to beta-blockers as per treating physician.
Intervention Arms: Participants will be
enteral (PO or by feeding tube). Recommended initial daily dose 40 mg (10 mg q 6 h). Recommended target daily dose 80 mg (20 mg q 6 h). Recommended maximal daily dose 160 mg (40 mg q 6 h).
Frequency:
enteral (PO or by feeding tube). Recommended initial daily dose 50 mg (25 mg q 12 h). Recommended target daily dose 100 mg (50 mg q 12 h). Recommended maximal daily dose 200 mg (100 mg q 12 h).
Freque
pre-existing anticonvulsant therapy for seizure disorder
early seizure requiring anticonvulsants
more than 72 hours elapsed since ICU admission.
Intervention Arms: Participants will be randomly a
Sponsors
Université Laval
Centre de recherche du CHU de Québec-Université Laval
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged =18 years 2. Admitted to the intensive care unit following acute TBI 3. Moderate or severe acute TBI (GCS =12 [on a scale of 3 to 15]) Each domain may have additional inclusion criteria
Exclusion criteria
Exclusion criteria: Platform trial exclusion criteria: 1. A decision to withdraw life-sustaining therapies was made Domain exclusion criteria: Beta-blocker domain: 1. Contraindications to use beta-blockers based on clinical risk (as per treating physician) Anticonvulsant domain: 1. Contraindications to use anticonvulsants based on clinical risk (as per treating physician) 2. Patient on anticonvulsants for seizure disorder prior to hospital admission 3. Early seizure requiring anticonvulsants 4. More than 72 hours have elapsed since ICU admission
Countries
Australia, Belgium, Brazil, Canada, Colombia, France, Ireland, Italy, Netherlands, New Zealand, Switzerland
Contacts
Public ContactAlexis;Larissa Turgeon;Belardin
;
Outcome results
None listed